Type 2 diabetes and hepatocellular carcinoma progression

Type 2 diabetes is a major risk factor for hepatocellular carcinoma. Cancer development is dependent on changes in the mechanics of the extracellular matrix, with increased rigidity favoring cancer progression in cirrhotic patients. Type 2 diabetes is marked by an accumulation of advanced glycation end products in the extracellular matrix. What is the impact of this phenomenon in non-cirrhotic subjects? In this study, this mechanism was investigated in animal models and in patients. Advanced glycation products are thought to promote changes in collagen architecture, improving the viscoelasticity of the extracellular matrix. In vivo, viscoelasticity could promote the progression of hepatocellular carcinoma, even in the absence of cirrhosis.